PMID- 38492020
OWN - NLM
STAT- Publisher
LR  - 20240316
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
DP  - 2024 Mar 16
TI  - Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a 
      multicenter retrospective study.
LID - 10.1007/s00277-024-05705-z [doi]
AB  - Elotuzumab-based regimens are sometimes selected for multiple myeloma treatment 
      after daratumumab-based regimens. However, there has been insufficient discussion 
      on the efficacy of elotuzumab after daratumumab. We used Kansai Myeloma Forum 
      registration data in a multicenter retrospective evaluation of the efficacy of 
      elotuzumab after daratumumab. Overall survival (OS) rate and time to next 
      treatment (TTNT) were significantly worse in the cohort given elotuzumab after 
      daratumumab (Dara cohort, n = 47) than in the cohort with no history of 
      daratumumab administration before elotuzumab (No-Dara cohort, n = 80, OS: 
      P = 0.03; TTNT: P = 0.02; best response: P < 0.01). In the Dara cohort, OS and 
      TTNT rates were worse with sequential elotuzumab use after daratumumab than with 
      non-sequential (OS: P = 0.02; TTNT: P = 0.03). In patients given elotuzumab < 180 
      days after daratumumab, OS (P = 0.08) and best response (P = 0.21) tended to be 
      worse, and TTNT was significantly worse (P = 0.01), than in those given 
      elotuzumab after >/= 180 days. These findings were confirmed by subgroup analyses 
      and multivariate analyses. Monoclonal-antibody-free treatment might be preferable 
      after daratumumab-based regimens. If possible, elotuzumab-based regimens should 
      be considered only >/= 180 days after daratumumab use.
CI  - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Nakamura, Naokazu
AU  - Nakamura N
AD  - Department of Hematology, Shinko Hospital, 1-4-47, Wakihamacho, Chuo-Ku, Kobe, 
      Hyogo, 651-0072, Japan. n_nakamura@kuhp.kyoto-u.ac.jp.
AD  - Department of Hematology and Oncology Graduate School of Medicine, Kyoto 
      University, Kyoto, Japan. n_nakamura@kuhp.kyoto-u.ac.jp.
FAU - Arima, Nobuyoshi
AU  - Arima N
AD  - Department of Hematology, Shinko Hospital, 1-4-47, Wakihamacho, Chuo-Ku, Kobe, 
      Hyogo, 651-0072, Japan.
FAU - Takakuwa, Teruhito
AU  - Takakuwa T
AD  - Department of Hematology, Osaka Metropolitan University Graduate School of 
      Medicine, Osaka, Japan.
FAU - Yoshioka, Satoshi
AU  - Yoshioka S
AD  - Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
FAU - Imada, Kazunori
AU  - Imada K
AD  - Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
FAU - Fukushima, Kentaro
AU  - Fukushima K
AD  - Department of Hematology and Oncology, Osaka University Graduate School of 
      Medicine, Suita, Japan.
FAU - Hotta, Masaaki
AU  - Hotta M
AD  - First Department of Internal Medicine, Kansai Medical University, Hirakata, 
      Japan.
FAU - Fuchida, Shin-Ichi
AU  - Fuchida SI
AD  - Department of Hematology, Japan Community Health Care Organization Kyoto 
      Kuramaguchi Medical Center, Kyoto, Japan.
FAU - Kanda, Junya
AU  - Kanda J
AD  - Department of Hematology and Oncology Graduate School of Medicine, Kyoto 
      University, Kyoto, Japan.
FAU - Uoshima, Nobuhiko
AU  - Uoshima N
AD  - Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
FAU - Shimura, Yuji
AU  - Shimura Y
AD  - Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural 
      University of Medicine, Kyoto, Japan.
FAU - Tanaka, Hirokazu
AU  - Tanaka H
AD  - Department of Hematology and Rheumatology, Faculty of Medicine, Kindai 
      University, Osakasayama, Japan.
FAU - Ohta, Kensuke
AU  - Ohta K
AD  - Hematology Ohta Clinic, Shinsaibashi, Japan.
FAU - Kosugi, Satoru
AU  - Kosugi S
AD  - Department of Internal Medicine (Hematology), Toyonaka Municipal Hospital, 
      Toyonaka, Japan.
FAU - Yagi, Hideo
AU  - Yagi H
AD  - Department of Hematology and Oncology, Nara Prefecture General Medical Center, 
      Nara, Japan.
FAU - Yoshihara, Satoshi
AU  - Yoshihara S
AD  - Division of Hematology, Department of Internal Medicine, Hyogo College of 
      Medicine, Nishinomiya, Japan.
FAU - Yamamura, Ryosuke
AU  - Yamamura R
AD  - Department of Hematology, Osaka Saiseikai Nakatsu Hospital, Nakatsu, Japan.
FAU - Adachi, Yoko
AU  - Adachi Y
AD  - Department of Internal Medicine, JCHO Kobe Central Hospital, Kobe, Japan.
FAU - Hanamoto, Hitoshi
AU  - Hanamoto H
AD  - Department of Hematology, Kindai University Nara Hospital, Nara, Japan.
FAU - Shibayama, Hirohiko
AU  - Shibayama H
AD  - Department of Hematology, National Hospital Organization Osaka National Hospital, 
      Osaka, Japan.
FAU - Hosen, Naoki
AU  - Hosen N
AD  - Department of Hematology and Oncology, Osaka University Graduate School of 
      Medicine, Suita, Japan.
FAU - Ito, Tomoki
AU  - Ito T
AD  - First Department of Internal Medicine, Kansai Medical University, Hirakata, 
      Japan.
FAU - Shimazaki, Chihiro
AU  - Shimazaki C
AD  - Department of Hematology, Japan Community Health Care Organization Kyoto 
      Kuramaguchi Medical Center, Kyoto, Japan.
FAU - Takaori-Kondo, Akifumi
AU  - Takaori-Kondo A
AD  - Department of Hematology and Oncology Graduate School of Medicine, Kyoto 
      University, Kyoto, Japan.
FAU - Kuroda, Junya
AU  - Kuroda J
AD  - Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural 
      University of Medicine, Kyoto, Japan.
FAU - Matsumura, Itaru
AU  - Matsumura I
AD  - Department of Hematology and Rheumatology, Faculty of Medicine, Kindai 
      University, Osakasayama, Japan.
FAU - Hino, Masayuki
AU  - Hino M
AD  - Department of Hematology, Osaka Metropolitan University Graduate School of 
      Medicine, Osaka, Japan.
CN  - Kansai Myeloma Forum
LA  - eng
PT  - Journal Article
DEP - 20240316
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
SB  - IM
OTO - NOTNLM
OT  - Daratumumab
OT  - Elotuzumab
OT  - Immune microenvironment
OT  - Multiple myeloma
EDAT- 2024/03/16 21:47
MHDA- 2024/03/16 21:47
CRDT- 2024/03/16 12:13
PHST- 2023/11/30 00:00 [received]
PHST- 2024/03/10 00:00 [accepted]
PHST- 2024/03/16 21:47 [medline]
PHST- 2024/03/16 21:47 [pubmed]
PHST- 2024/03/16 12:13 [entrez]
AID - 10.1007/s00277-024-05705-z [pii]
AID - 10.1007/s00277-024-05705-z [doi]
PST - aheadofprint
SO  - Ann Hematol. 2024 Mar 16. doi: 10.1007/s00277-024-05705-z.